Systematic comparison of the male reproductive tract in fetal and adult Wistar rats exposed to DBP and DINP in utero during the masculinisation programming window.


Journal

Toxicology letters
ISSN: 1879-3169
Titre abrégé: Toxicol Lett
Pays: Netherlands
ID NLM: 7709027

Informations de publication

Date de publication:
15 Dec 2020
Historique:
received: 19 05 2020
revised: 14 10 2020
accepted: 14 10 2020
pubmed: 22 10 2020
medline: 29 12 2020
entrez: 21 10 2020
Statut: ppublish

Résumé

This study investigates possible effects of in utero exposure of rats to a low dose (125 mg/kg bw/day) and a high dose (750 mg/kg bw/day) of Diisononyl phthalate (DINP) during the masculinisation programming window (MPW) which is embryonic days 15.5-18.5 (e15.5 - e18.5). Dibutyl phthalate (DBP) was used at a high dose level (750 mg/kg bw/day) as an established positive control substance for anti-androgenic effects on the developing male reproductive tract. We focussed on the MPW and measured a multitude of biological endpoints at various life stages and applied state of the art histopathology staining techniques to refine the characterization of potential changes to the testis, beyond what is currently available with DINP. If DINP can mediate testicular dysgenesis (TDS) disorders, this exposure window would be sufficient to induce androgen impacts and alter male reproductive tract development as shown earlier in this validated experimental model with DBP. Overall, the results of this systematic comparison provide convincing evidence on the differences between the effects occurring with DBP and DINP. In contrast to what was seen with DBP, DINP did not cause cryptorchidism or hypospadias, had no effect on anogenital distance/anogenital index (AGD/AGi) and Leydig cell aggregates on e17.5 and e21.5 did not increase. With DINP no reduction of intratesticular testosterone, no effects on sperm motility and sperm count and no effect on adult testosterone or luteinizing hormone (LH) levels were seen. Our results demonstrate that DINP does not cause the adverse reproductive effects known to occur with DBP, a well-established endocrine disruptor.

Identifiants

pubmed: 33086118
pii: S0378-4274(20)30443-4
doi: 10.1016/j.toxlet.2020.10.006
pii:
doi:

Substances chimiques

Endocrine Disruptors 0
Phthalic Acids 0
Dibutyl Phthalate 2286E5R2KE
Testosterone 3XMK78S47O
diisononyl phthalate 4010KIX4CK

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

37-50

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors from the University of Edinburgh declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Sander van den Driesche (S)

Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom; ZJU-UoE Institute, Zhejiang University, Haining, China.

Serena Shoker (S)

Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.

Fiona Inglis (F)

Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom.

Christine Palermo (C)

ExxonMobil Biomedical Sciences, Clinton, New Jersey, United States.

Angelika Langsch (A)

BASF SE, Ludwigshafen, Germany.

Rainer Otter (R)

BASF SE, Ludwigshafen, Germany. Electronic address: rainer.otter@basf.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH